Saponin-based adjuvant immune stimulation

Saponin-based immune stimulation refers to the use of plant-derived saponins as **adjuvants** in vaccines to enhance immune responses. Saponins, triterpene or steroid glycosides, are not a discrete molecular target but a broad class of compounds known for their immune modulatory properties. They function by promoting cytokine and chemokine production, enhancing activity and maturation of antigen-presenting cells (mainly dendritic cells), stimulating both humoral (antibody) and cellular (T cell, including CD8+ cytotoxic T cell) immune responses, and increasing antigen cross-presentation. Saponin-based adjuvants, especially those containing QS-21 from *Quillaja saponaria*, are used in several approved vaccines (e.g., Shingrix, Mosquirix, Novavax COVID-19 vaccine). The immune-stimulatory action relies on complex effects including membrane interaction, activation of innate pattern recognition receptors, and synergy with other adjuvants (e.g., in AS01 or nanoformulations combining TLR agonists). Saponin-based immune modulation is **not a singular classical drug target**—rather, it is a composite immunostimulatory approach involving multiple molecular and cellular mechanisms[1][2][3][4][5].

Other names

Saponin immune stimulationSaponin-based adjuvantSaponin adjuvantSaponin-based immune adjuvantSaponin immunomodulation

Activation of antigen-presenting cells (e.g., dendritic cells) Enhancement of antigen cross-presentation Induction of Th1 and Th2 responses Stimulation of cytokine and chemokine release Promotion of CD8+ T cell-mediated immunity